1 ml vial tirzepatide Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity Compounded Tirzepatide GLP-1 Weight Loss

In the ongoing global pursuit of effective obesity pharmacotherapies, the clinical effectiveness of investigational agents is paramount

Our home delivery plans stay the same month to month

By activating two separate hormonal pathways simultaneously, Tirzepatide: Dramatically reduces appetite and food cravings Slows gastric emptying, helping you feel full longer Improves insulin sensitivity and blood sugar regulation Reduces inflammation and supports metabolic health Signals the brain's hunger and reward centers to decrease the drive to overeat In clinical trials (the SURMOUNT program), patients lost an average of 2022% of their body weight over 72 weeks, results that rival bariatric surgery, without going under the knife

Patients should maintain balanced nutrition despite reduced appetite and report severe abdominal pain or persistent vomiting urgently